Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of apremilast in pediatric moderate to severe plaque psoriasis
MOH_2021-04-11_009883Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of apremilast in plaque psoriasis (2 arms), sponsored by Amgen. Primary endpoint: Long-term safety of apremilast. Started Mar 2021; status: recruiting.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2021-04-11_009883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-11_009883.